WO2005092323A1 - LXRα受容体特異的部分アゴニスト - Google Patents
LXRα受容体特異的部分アゴニスト Download PDFInfo
- Publication number
- WO2005092323A1 WO2005092323A1 PCT/JP2005/005142 JP2005005142W WO2005092323A1 WO 2005092323 A1 WO2005092323 A1 WO 2005092323A1 JP 2005005142 W JP2005005142 W JP 2005005142W WO 2005092323 A1 WO2005092323 A1 WO 2005092323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lxr
- receptor
- cholesterol
- group
- lxrα
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
Definitions
- LXR a receptor specific partial agonist
- the present invention relates to an atherosclerotic heart based on the promotion of cholesterol excretion (HDL regeneration) from peripheral cells by human liver X receptor a (LXR ⁇ ) receptor-specific ligand.
- the present invention relates to a method for preventing and treating the progress of a disease and its related conditions.
- Atherosclerosis is a general term for several diseases in which the wall of an artery becomes thick and loses flexibility. The most important and most common of these diseases is atherosclerosis, in which fat-rich substances accumulate below the lining of the arterial wall. Atherosclerosis occurs mainly in the aorta, carotid artery, and coronary artery, and is recognized as a causative factor for cardiovascular diseases such as stroke and heart attack.
- Atherosclerosis is a pathological condition characterized by patchy thickening of the inner lining of arteries, and the thickened plaque portion (atheroma plaque or atheroma) contains a large amount of cholesterol. It is formed when macrophages take up a large amount of oxidized low-density lipoprotein (oxidized LDL), enter the gaps between endothelial cells in the blood vessel wall, and form foam cells with cholesterol.
- oxidized LDL oxidized low-density lipoprotein
- Arteries affected by atherosclerosis lose elasticity, and the arteries narrow as the atherosclerosis grows. Over time, calcium deposits accumulate in the atheroma and become brittle or rupture. The ruptured atheroma is engulfed by blood and causes the atheroma to expand, making the arteries even smaller. In addition, the ruptured atheroma can shed fatty content and trigger the formation of blood clots (thrombus). Blood clots can further narrow the artery or cause occlusion at that location, and can loosen and travel along the bloodstream where they can cause occlusion.
- Preventing atherosclerosis requires eliminating manageable risk factors (such as high blood cholesterol levels). For this reason, prevention is a cholesterol-lowering product This is done by the start of a program.
- LXR Human liver X receptor
- a cholesterol sensor protein was found in the liver, which can convert cholesterol in the body into bile acids and excrete it.
- the nuclear receptor LXR contains spleen (NR1H3) and j3 (NR1H2), which are highly expressed mainly in the liver and small intestine, and ⁇ is ubiquitously present throughout the body.
- This LXR acts as an endogenous agonist for cholesterol metabolites (oxesterols) which increase in proportion to cholesterol content.
- LXR monument cholesterol 7 alpha is the rate-limiting enzyme for producing a bile acid - Ru important receptors der to promote transcription of the hydroxylase (CYP7A1).
- LXRa knockout mice In LXR a knockout mice, the induction of CYP7A1 expression observed in wild-type mice fed a high cholesterol diet was not observed, and LXR senses the cholesterol content in the liver to reduce excess cholesterol. It was clarified that bile acids were catabolized and reduced. It has also been demonstrated that the expression of ATP-binding cassette membrane transporters ABCG5 and ABCG8, which are responsible for cholesterol excretion from the liver to bile, is induced by LXRa.
- LXR agonists have the effect of pumping cholesterol from peripheral tissues, returning it to the liver and excreting it from the liver, and can be expected to be an arteriosclerosis improving drug.
- side effects such as elevated serum triglycerides were observed.
- an object of the present invention is to provide an LXR useful for prevention and treatment of diseases related to arteriosclerosis.
- the present inventors conducted a search for LXR-specific agonists using the reporter Gene Atssay and found that riccardin C (RC), which is a cyclic bisbenzyl compound represented by the following formula (2), The present inventors have found that specific partial agonist activity exists, and completed the present invention based on this finding.
- RC riccardin C
- the action of the compound according to the present invention is characterized in that it is a LXR-specific partial agonist.
- an object of the present invention is to provide a method for inducing the expression of the ABCA1 gene, the method including a step of increasing the serum HDL level of a patient requiring such treatment.
- the present invention includes the following inventions.
- a pharmaceutical composition for preventing or treating an LXRct-related disease comprising a cyclic bisbenzyl compound represented by the following formula (1) or a pharmaceutically acceptable salt or hydrate thereof.
- R 1, R 2 and R 3 each independently represent a hydrogen atom, an acyl group, an alkyl group,
- R is a methyl group, and R and R are
- the pharmaceutical composition of the present invention selectively activates LXRa to increase HDL production, and more specifically, to increase HDL production through regulation of ABCA1 gene expression (increase in expression). causess an increase.
- the pharmaceutical composition according to the present invention acts as a preventive or therapeutic agent for LXR-associated diseases based on a potent LXRa selective activating effect.
- the present invention enables the preparation of a drug useful for increasing HDL levels. Furthermore, the present invention can be used for preparing a useful drug for reducing the risk of developing a disease related to atherosclerosis or the like or for treating a patient who has already developed the disease.
- the compound described in the present specification which is a partial agonist, can be expected to have an effect of reducing side effects.
- FIG. 1A is a view showing the results of a reporter gene assay on LXR response elements with various concentrations of a test compound in CV_1 cells.
- FIG. 14 is a diagram showing the results of reporter gene attestation for a report.
- FIG. 2A shows the results of a ligand competition experiment in which a test compound and LXR agonist TO901317 were tested for their ability to compete with the LXR a receptor for binding.
- FIG. 2B is a view showing the results of a ligand competition experiment in which a test compound and LXR agonist TO901317 were tested for their ability to compete with the LXR ⁇ receptor for binding.
- FIG. 2C is a view showing the results of a test on the binding of a test compound to an LXR ⁇ receptor in the absence of LXR agonist TO901317.
- FIG. 4 shows the results of measuring the effect of test compounds on cholesterol excretion in THP_1 cells.
- LXRa-related disease means a disease that can be improved by activating LXRa, preferably by selectively activating LXRa, and typically includes LXR agonist, preferably a disease which can be ameliorated by the action of an LXR a selective agonist.
- LXR spleen-related diseases include arteriosclerosis such as atherosclerosis, chronic inflammatory diseases such as rheumatoid arthritis, metabolic disorders such as diabetes, cirrhosis, cholelithiasis, hyperlipoproteinemia, Alzheimer's disease, and anemia. It includes at least one disease selected from the group consisting of breast cancer, colorectal cancer, prostate cancer, leukemia and the like.
- This treatment can be used in any patient who desires an increase in serum HDL.
- Patients amenable to such treatment are those with HDL levels below the clinically desired level (less than about 40 mg / dl).
- the LXR receptor-specific ligand is a unit preparation containing a conventional non-toxic pharmaceutically acceptable carrier, adjuvant, and vehicle, and is orally administered, rectally administered, It can be administered topically, parenterally (including subcutaneous injection, intravenous, intramuscular, intrasternal injection or infusion), ophthalmic administration (eye drops) or inhalation spray (pulmonary or nasal administration).
- the dose of the LXRa receptor-specific ligand is usually 0.1 to 150 mg / kg of body weight, preferably 1 to 50 mg / kg of body weight.
- the administration subject is a mammal, usually a human.
- the pharmaceutical composition containing the active ingredient described in the present specification can be produced by a conventional pharmaceutical compounding technique.
- tablets, troches, lozenges, aqueous or oily suspensions, hard or soft capsules, or syrups or elixirs can be in a form suitable for oral use.
- Oral compositions can be prepared according to methods known in the art of manufacture, and such compositions for oral dosage form should be prepared to contain one or more drugs, usually selected from pharmaceutical media.
- Can be. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- Suitable excipients include, but are not limited to, for example, inert diluents (such as dicalcium phosphate), disintegrants (such as corn starch, potato starch, and alginic acid), and binders (such as tragacanth gum acacia).
- inert diluents such as dicalcium phosphate
- disintegrants such as corn starch, potato starch, and alginic acid
- binders such as tragacanth gum acacia.
- lubricants magnesium stearate etc.
- sweeteners saccharin etc.
- compositions containing a compound including a pharmaceutically acceptable salt or a hydrate thereof are also included in the scope of the present invention.
- R, R, and R each independently represent a hydrogen atom, an acyl group (eg, an acetyl group,
- a metal salt may be used to dissolve the compound in water.
- R is a hydrogen atom.
- R and R are both hydrogen atoms, R is a hydrogen atom
- salts can be administered The choice may be made of salts with organic or inorganic bases which do not harm or inconvenience the body and the environment of administration. Such salts are formed from monovalent or polyvalent ions, particularly preferred are inorganic ions such as sodium, potassium, magnesium, calcium and the like.
- riccardin C which was found as a partial agonist capable of specifically activating LXR from a natural compound library
- Atsusei was compared using riccardin F (RF) shown in the following structural formula as a target compound.
- Riccardin F is a compound represented by the following formula (3), which is substituted with a hydroxyl catalyl group at the 14-position of riccardin C, which is an LXRa-specific partial agonist in the present application.
- Atsey was performed by transient transfection of CV-1 cells and tested for its ability to activate human LXRa and human LXR beta isoforms using the natural compound library as a search source.
- Cells were transformed with an LXRa expression vector and a human LXR ⁇ expression vector, a control plasmid containing a human LXR expression vector, a reporter construct having a firefly luciferase gene linked to LXRE, and a LacZ construct linked to SV40. We transfeeted together.
- riccardin C functions as an agonist selectively over LXR.
- riccardin F had no effect on both ⁇ and ⁇ , suggesting that the hydroxyl group at position 14 plays an important role in this activation.
- the binding to the synthetic peptide having LXXLL caused by the ligand binding to human LXR and human LXR / 3 receptor is analyzed based on the fluorescence deflection method.
- the human LXRs ligand binding domain (LBD) was expressed and prepared as a GST-labeled fusion protein in E. coli BL21.
- FIG. 2A shows the effect of various concentrations of a test compound (RF or RC) on the fluorescence polarization of human LXR a -GST protein in the presence of TO901317 (1 ⁇ M).
- FIG. 2B shows the effect of various concentrations of the test compound (RF or RC) on the fluorescence polarization of human LXR ⁇ -GST protein in the presence of TO901317 (1 ⁇ M).
- Figure 2C in the absence TO901317, showing the effect against the fluorescence polarization of the human LXR alpha -GST proteins of the test compound at various concentrations (RF or RC).
- riccardin F alone had little effect on the degree of fluorescence deflection to LXR, and did not show the recruitment activity of coactivator.
- Riccardin C specifically bound to the LXR receptor LBD and antagonistically inhibited the action of the potent LXR synthetic ligand TO901317.
- the antagonistic activity against LXR / 3 against TO901317 was not shown, and the results also showed the specificity of riccardin C for LXR. Therefore, it was revealed that riccardin C is a specific partial agonist for LXR.
- THP-1 cells cultured in RPMI medium containing 10% FCS were incubated in serum-free medium (0.2% BSA) containing the test reagent. 24 hours later,
- RNAeasy QIAGEN
- Quantitative PCR was performed using a 7700 Sequence Detector (ABI) and a TaqMan-mRNA quantification system. In short, about 150 ng of DNase-treated mRNA is reverse transcribed and the oligonucleotide probe
- the cells treated with riccardin C are about 1.8 times higher than the cells not treated with the drug.
- THP-1 cells cultured in 10% FCS medium were cultured in a serum-free medium (0.2% BSA) containing the test compound for 24 hours.
- Cholesterol contained in the medium was prepared by extracting the medium with 4 times the volume of chloroform / methanol (2: 1) and washing the organic solvent layer with an equal amount of 50% methanol.
- Intracellular cholesterol was prepared by extracting cells with hexane / isopropanol (3I2). The cholesterol level in the obtained crude extract was measured by quantification of a quinone dye produced by the cholesterol oxidase method (Determina LTCII; Kyowa Medettas).
- FIG. 4 shows that cholesterol excretion from THP-1 cells due to the action of riccardin C is increased.
- riccardin C has an effect of promoting HDL production, suggesting that it is effective for preventing or treating the progression of atherosclerotic heart disease and its related conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511460A JP5028594B2 (ja) | 2004-03-29 | 2005-03-22 | LXRα受容体特異的部分アゴニスト |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-094177 | 2004-03-29 | ||
JP2004094177 | 2004-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092323A1 true WO2005092323A1 (ja) | 2005-10-06 |
Family
ID=35055969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005142 WO2005092323A1 (ja) | 2004-03-29 | 2005-03-22 | LXRα受容体特異的部分アゴニスト |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5028594B2 (ja) |
WO (1) | WO2005092323A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228455A (zh) * | 2011-05-05 | 2011-11-02 | 山东大学 | 双联苄类化合物在制备抗炎药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58208286A (ja) * | 1982-05-28 | 1983-12-03 | Otsuka Pharmaceut Co Ltd | ビスビベンジルジエ−テル誘導体 |
-
2005
- 2005-03-22 WO PCT/JP2005/005142 patent/WO2005092323A1/ja active Application Filing
- 2005-03-22 JP JP2006511460A patent/JP5028594B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58208286A (ja) * | 1982-05-28 | 1983-12-03 | Otsuka Pharmaceut Co Ltd | ビスビベンジルジエ−テル誘導体 |
Non-Patent Citations (4)
Title |
---|
ASAKAWA Y. ET AL: "Riccardin A and riccardin B, two novel cyclic bis(bibenzyls) possesing cytotoxicity from the liverwort Riccardia multifida(L) S. Gray.", JOURNAL OF ORGANIC CHEMISTRY., vol. 48, no. 13, 1983, pages 2164 - 2167, XP002990145 * |
EICHER T. ET AL: "Synthesis of cyclic bis-bibenzyl systems.", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY., no. 5, 1998, pages 877 - 888, XP001056010 * |
SCHWARTNER C. ET AL: "Effect of marchantins and related compounds on 5-lipoxygenase and cyclooxygenase and their antioxidant properties: a structure activity relationship study.", PHYTOMEDICINE., vol. 2, no. 2, 1995, pages 113 - 117, XP002989421 * |
YOSHIDA T. ET AL: "Phenolic constituents of the liverwort: four novel cyclic bisbibenzyl dimers from Blasia pusilla L.", TETRAHEDRON., vol. 52, no. 46, 1996, pages 14487 - 14500, XP004105050 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228455A (zh) * | 2011-05-05 | 2011-11-02 | 山东大学 | 双联苄类化合物在制备抗炎药物中的应用 |
CN102228455B (zh) * | 2011-05-05 | 2014-07-16 | 山东大学 | 双联苄类化合物在制备抗炎药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005092323A1 (ja) | 2008-02-07 |
JP5028594B2 (ja) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Uppal et al. | Activation of LXRs prevents bile acid toxicity and cholestasis in female mice | |
EP2282778B1 (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis | |
Dahl et al. | Pharmacokinetics of chlorpromazine after single and chronic dosage | |
KR100394157B1 (ko) | 아테롬성동맥경화증및기타심혈관질환및염증질환의치료방법 | |
JP5933258B2 (ja) | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 | |
JP4825977B2 (ja) | Fxr活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤 | |
JP2016520130A (ja) | 心臓疾患における新規治療戦略としてのbet阻害 | |
CA3002924A1 (en) | Analogs of celastrol | |
JP2019011343A (ja) | 選択的s1p1レセプターアゴニストを含む薬学的合剤 | |
JP2011500602A (ja) | N−アシルエタノールアミン−加水分解酸性アミダーゼを阻害する組成物及び方法 | |
BR112019017312A2 (pt) | combinação de um agonista de ppar com um agonista de fxr | |
JP2016529224A (ja) | レット症候群およびその処置 | |
AU2007204410A1 (en) | Combination of mTOR inhibitor and antipolate compound | |
WO2012112670A1 (en) | Novel lipogenic inhibitors and uses thereof | |
KR20020093983A (ko) | 포스페이트 수송 억제제 | |
WO2016054056A1 (en) | Methods of treating pxe with tnap inhibitors | |
JP5028594B2 (ja) | LXRα受容体特異的部分アゴニスト | |
UA97123C2 (uk) | Застосування індазолметоксиалканової кислоти для зниження рівнів тригліцериду, холестерину та глюкози | |
JP2005281155A (ja) | Fxr活性化を介したコレステロールホメオスタシス関連遺伝子転写活性調節剤 | |
Heinonen | Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis? | |
WO2015034010A1 (ja) | 核内受容体肝臓x受容体アゴニスト | |
Kharbanda et al. | In silico designing, in vitro and in vivo evaluation of potential PPAR-γ agonists derived from aryl propionic acid scaffold | |
CN107530355A (zh) | (4‑羟基‑2‑甲基‑1,1‑二氧‑2H‑苯并[e][1,2]噻嗪‑3‑基)(萘‑2‑基)甲酮在预防和/或治疗非酒精性脂肪性肝炎中的用途 | |
JP2004123716A (ja) | 化学物質に起因する肝障害の予防及び/又は治療のための医薬 | |
Mucke | Drug Repurposing Patent applications January–March 2020 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511460 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |